Distinguishing Toxicity in Combination Regimens and Managing Long Term Tolerability in Advanced RCC

As the discussion continues, attention turns to differentiating toxicities in combination regimens. When patients receive combinations such as IO plus TKI or belzutifan based regimens, overlapping symptoms can complicate attribution.

Panelists describe a practical approach: when uncertainty exists, hold the TKI component first due to its shorter half life and assess for improvement. Anemia and hypoxia are more consistent with HIF-2 inhibition, while gastrointestinal and dermatologic toxicities may be more typical of VEGF targeted TKIs. Immune related causes must also be considered when appropriate.

The group emphasizes evaluating reversible contributors, such as thyroid dysfunction, and in cases of anemia, considering whether the mechanism is treatment related. Unlike clinical trials, real world practice allows dose flexibility, including reductions below protocol specified doses and creative scheduling adjustments.

The discussion also touches on treatment discontinuation due to toxicity. In clinical practice, a subset of patients stop therapy because of adverse effects rather than progression. Cumulative toxicity across multiple lines, including proteinuria, renal dysfunction, and dermatologic effects, becomes increasingly relevant. Collaboration with specialists and thoughtful dose modification can sometimes allow rechallenge.

This segment reinforces that managing toxicity is a dynamic process requiring stepwise evaluation and individualized adjustment.